Stock Alert: Inovio Stock Up 8% In Late Trade On Interim MERS-CoV Vaccine Data

(RTTNews) - Shares of Inovio Pharmaceuticals Inc. (INO) rose over 8.15% to $14.87 in after-hours session on April 28, after the company and GeneOne Life Science announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700, also called GLS-5300, for MERS coronavirus or MERS-CoV.

Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg of INO-4700, a DNA vaccine that targets the MERS-CoV Spike glycoprotein, delivered with intradermal CELLECTRA device.

Further, INOVIO is planning to advance INO-4700 into a Phase 2 clinical trial in the Middle East with a previously announced funding of $56 million by the Coalition for Epidemic Preparedness Innovations or CEPI.

The stock has been trading between $1.92 and $19.36 in the past one year, and closed Tuesday's regular trade at $13.75, up 5 cents or 0.36%. INO, further, gained $1.12 or 8.15% in the after-hours trading session.